



GV-SOLAS

Gesellschaft für Versuchstierkunde
Society for Laboratory Animal Science

Expert Information

From the Working Group on Hygiene

**Implication of infectious agents on
results of animal experiments**

Lymphocytic Choriomeningitis Virus

Status September 2020

Authors: GV-SOLAS Working Group on Hygiene

Contents

Background	3
Prevalence	3
Host species.....	3
Properties.....	3
Susceptibility	4
Organotropism.....	4
Clinical disease	4
Pathology	4
Morbidity and mortality	5
Zoonotic potential	5
Interference with research	5
<i>Oncology</i>	6
<i>Teratology</i>	6
<i>Infectiology / Interactions with other infectious agents</i>	6
<i>Immunology</i>	6
<i>Toxicology</i>	6
<i>Physiology</i>	6
<i>Cell biology</i>	6
<i>Assisted reproductive technology</i>	6
Special considerations.....	6
References.....	8

Lymphocytic Choriomeningitis Virus (LCMV)

Background

- LCMV is the causal agent of lymphocytic choriomeningitis in humans.^{1,2,3,4}
- LCMV was first isolated as cause of aseptic meningitis among hospitalized patients in St. Louis in the early 1930s.^{5,6}
- After 1935 many lab colonies of mice were found to be infected with LCMV in the USA⁷ and Japan.⁸
- Wild house mouse was identified as reservoir of LCMV in the late 1930s.⁹
- Between 1933 and 2008 over twenty-three different virus strains with high genetic diversity were identified.¹⁰

Prevalence

- Prevalence of LCMV among wild mouse populations: In Germany (in the early 1960s) 3% of samples were positive¹¹, in the UK about 4%¹², in Japan 9-25%^{13,14}, in Australia 0%¹⁵, in the USA 3.9-13.4%¹⁶, in China 2 %¹⁷, and in Spain up to 9 %¹⁸
- The prevalence of LCMV among laboratory mice is actually low: North America 1%, Europe 2%¹⁹ respectively 0%^{20,21}, France 2%²², Taiwan 4%²³, Japan 2-5.6%.²⁴
- Prevalence of LCMV in hamster inbred strains^{25,26} is up to 2.2 % of hamsters.²⁴
- Transplantable hamster tumors, different cell lines and monoclonal antibodies are potential carriers of LCMV.^{27,28}
- In laboratory rats, LCMV is normally not found.^{19,20,21,23}
- Prevalence of LCMV antibodies in human populations range from 2% to 5% indicating previous exposure and infection.^{16,18,29,30}

Host species

- Natural hosts for LCMV are laboratory and wild mice, pet and laboratory hamsters. These hosts transmit virus.^{31,32,33}
- Aberrant hosts are most rodents, dogs, non-human primates and humans.^{12,16,34-36} These hosts do not transmit virus.^{37,38}
- Guinea pigs, rats and baboons can be infected experimentally.³⁶
- LCMV can be a contaminant of transplantable tumours.^{27,28} Continuous cell lines may also be virus carriers, e.g. neuroblastoma¹⁸ and baby hamster kidney cells (BHK-21).

Properties

- LCMV is a rodent borne single-stranded RNA virus that belongs to the Arenaviridae.^{39,40}
- Different strains of LCMV have been isolated: strains Armstrong, Traub and WE in the early 1930s in the USA⁴¹, strains OQ28 and BRC decades later.⁴² Additional strains were identified in *Mus musculus*.⁴³
- Different LCMV strains possess different virulences for guinea pig and hamster strains^{25,26} as well as neonatal rats.⁴⁴
- LCMV is transferred from natural hosts to others by contact with saliva, nasal secretions, or urine.^{45,46}

- In natural infections of immunocompetent animals, virus is only shed by hamsters and mice infected prior to weaning.⁴⁵⁻⁴⁸
- Among enzootic infected populations of mice, the most common route of transmission is congenital in utero.⁴⁵⁻⁴⁷

Susceptibility

- Laboratory mouse strains (e.g. SWR/J, DBA/2, C57Bl/6, CBA/J) differ greatly in susceptibility to infection with different LCMV strains.⁴⁹
- Laboratory rats and wild rats are not affected by natural LCMV infection.^{19-21,50}
- Many laboratory rodents can experimentally be infected by LCMV, e.g. guinea pigs.⁵¹ and rats.⁵²

Organotropism

- Kidney
- Liver
- Brain⁵³
- Salivary glands
- Lymphohaematopoietic system³⁸
- Involvement of spleen, lymph nodes, adrenal glands, intestine, pancreas, and central nervous system is variable³⁵

Clinical disease

- Natural infections in mice and hamsters can be perinatal persistent infections with late onset disease (or chronic immune complex disease): wasting at 7-10 months of age.^{33,48}
- LCMV causes a lifelong symptomless infection in mice.^{45,46}
- In humans, LCMV induces febrile illness, influenza-like symptoms¹, sensorineural deafness, labyrinth damage and meningeal involvement.⁵⁴
- Clinical disease after experimental infection is influenced by the route of inoculation: parenteral inoculation induces visceral form in mice with asymptomatic conjunctivitis, ascites, and somnolence.^{53,55}
- Intracerebral inoculation produces lymphocytic choriomeningitis^{45,46} and autoimmune haemolytic anaemia in different strains of mice.⁵⁶
- In adult mice, some LCMV strains infiltrate splenic white pulp, ablate cytotoxic T-lymphocyte response and produce persistent infection, while other genetically closely related strains do not.⁵⁷
- In newborn rats, different LCMV strains induce diseases with various pathology in spleen and brain, individual behavioral deficits, several neuropathologies in the cerebellum and different immune responses to infection.⁴⁴
- In rhesus macaques, the WE strain of LCMV causes a fatal hepatitis, while the Armstrong strain causes no disease.⁵⁸

Pathology

- Natural infection in mice and hamsters:
 - Perinatal: antigen-antibody-immune-complex glomerulonephritis at the age of 7-10 months

- Chronic disease: inflammatory lesions in many organs like glomerulonephritis, focal hepatic necrosis and disseminated lymphoid infiltrations in several body tissues^{53,55}
- Experimental infection: T-cell mediated immune disease:
 - Murine hepatitis^{59,60}
 - Lesions in the urinary tract: urolithiasis, hydronephrosis, cystitis and pyelonephritis⁶¹ in Lewis rats after intracerebral injection
 - Liver degeneration (necrosis and inflammation), involvement of spleen, lymph nodes, adrenal glands, intestine, pancreas and central nervous system in marmosets and tamarins. LCMV antigens are isolated from necrotic foci and in non-degenerated organs like lung, kidney, urinary bladder, brain and testis.³⁵

Morbidity and mortality

- LCMV strain ARM is avirulent for different hamster strains and guinea pigs.^{25,62}
- LCMV strain WE causes 100% mortality⁶³ respectively high morbidity in guinea pigs⁵¹ and high morbidity in inbred Syrian gold hamsters.²⁶
- Naturally infection of mice and hamsters: high rate of infection, low rate of morbidity^{45,46}
- *Foxn1^{nu}* mice without T-Lymphocytes develop high virus levels without morbidity like hepatitis and glomerulonephritis after intracerebral or intraperitoneal inoculation.^{59,64-66}
- Morbidity and mortality in experimental infections depend on the way of infection, host species and age. Intracerebral infection of mice: 60-100% morbidity, 40-100% mortality; intraperitoneal infection of mice: 60% morbidity, no mortality^{45,46}

Zoonotic potential

- Among 713 hospitalized patients with encephalitis 8% were associated with LCMV.⁶⁷
- Wild mice are the natural reservoir of infection.^{11,68}
- Golden hamster supplanted house mice as the major source of LCMV infection and transmit the virus to humans.^{48,69,70}
- Many human cases of LCMV infection are described.⁷¹⁻⁷³
- Human infections with LCMV arise from contact with infected animals, human to human congenital infection,^{74,75} infection by transplantation of organs⁷⁶⁻⁷⁸ or infection after needle stick injury.⁷⁹
- Most human LCMV infections are linked to pet rodents and inhalation (aerosol, droplets), fomites, direct contact with excreta, blood, saliva.¹
- LCMV infection of laboratory workers is associated with lab animals,^{50,80} cultured tissues from infected mice or hamsters.
- Congenital LCMV infection in humans has been described in Europe in 1955⁷⁴ and in the USA in 1993.^{75,81}
- LCMV has a teratogenic effect in the case of congenital infection in humans and is strongly neurotropic in the human fetus.⁸²
- LCMV can cross the placenta, infect the developing fetus and induces severe and permanent injury.⁸³

Interference with research

- Animals that carry LCMV are generally not suitable for experiments.

- The most important impact associated with an LCMV-infected colony is the potential infection of workers.

Oncology

- LCMV influences experimental oncology, enhances the frequency of lymphoma after treatment with carcinogen.³
- LCMV enhances the susceptibility for transplantable tumor cell lines.⁸⁴
- LCMV enhances the survival time of leukemia-transplanted guinea pigs.⁸⁵
- LCMV can enhance the incidence of lymphomas and can decrease the incidence of mammary tumors in mice.⁸⁶

Teratology

- No data

Infectiology / Interactions with other infectious agents

- Interference with Rauscher virus: decreased incidence of leukaemia in mice.⁸⁷

Immunology

- LCMV influences humoral and cellular immune responses.⁸⁸
- LCMV causes a long-lasting immunodepression with decrease of proliferation capacity of splenic T-lymphocytes.⁸⁹⁻⁹³
- LCMV induces polyclonal cytotoxic T-lymphocyte stimulation.^{94,95}
- Neonatally or congenitally infected mice have a lifelong chronic LCMV infection⁹⁶ and viraemia.⁹⁷
- LCMV enhances interleukin 12-mediated immunotoxicities.^{99,100}
- LCMV induces different expression of alpha/beta interferons.¹⁰¹
- LCMV induces a transient bone marrow aplasia.¹⁰²

Toxicology

- No data

Physiology

- Growth hormone deficiency, reduced weight and serum glucose levels can occur in different mice strains.^{103,104}

Cell biology

- No data

Assisted reproductive technology

- No data

Special considerations

- The history of LCMV correlates with the development of modern immunology.^{105,106}
- LCMV infection is an important model for immunological research. Several key concepts have been discovered: persistent viral infection,^{45,46,107} MHC restriction,^{108,109}

T cell memory and T cell exhaustion,¹¹⁰ key role of immune pathology in disease,^{105,106,111} discovery of mechanisms of immuntolerance.¹¹²

- In 1996 Nobel prizes were awarded to Peter Doherty and Rolf Zinkernagel who used LCMV as a model to enumerate the immunobiology of virus persistence and differential immune responses based on modes of transmission.¹⁶

Updated by Karin Jacobi, Berlin, September 2020

References

1. Maetz HM, Sellers CA, Bailey WC, Hardy GE. 1976. Lymphocytic choriomeningitis from pet hamster exposure: a local public health experience. *Am J Public Health* 66:1082-1085.
2. Ackermann R. 1977. Risk to human through contact with golden hamsters carrying lymphocytic choriomeningitis virus. *Dtsch Med Wochenschr* 102:1367-1370.
3. Garman RH, Bowen GS, Fowler EH, Kraus AL, Newman AL, Rifkin BR, Andrews EJ, Winkler WG. 1977. Lymphoma associated with an epizootic of lymphocytic choriomeningitis in Syrian hamsters (*Mesocricetus auratus*). *Am J Vet Res* 38:497-502.
4. Lehmann-Grube F, Ibischer B, Bugislaus E, Kallay M. 1979. A serological study concerning the role of the Golden hamster (*Mesocricetus auratus*) in transmitting lymphocytic choriomeningitis virus to humans. *Med Microbio Immunol-Berl* 167:205-210.
5. Armstrong CL, Lillie RD. 1934. Experimental Lymphocytic Choriomeningitis of monkeys and mice produced by a virus encountered in studies of the 1933 St. Louis Encephalitis Epidemic. *Public Health Rep.* 49:1019–1020. doi: 10.2307/4581290.
6. Rivers TM, Scott TFM. 1935. Meningitis in man caused by a filterable virus. *Science* 109:439–440. doi:10.1126/science.81.2105.439-a.
7. Traub E. 1935, *Science* 81 (2099):298-299.
8. Kasahara S, Hamano R, Yamada R, Tsubaki S. 1937. Choriomeningitis virus isolated in the course of experimental studies on epidemic encephalitis. *Trans Soc Pathol Jpn* 27:581-585 (in Japanese).
9. Armstrong C, Sweet LK. 1939 Lymphocytic choriomeningitis *Public Health Rep* 54(17):673-684, doi: 10.2307/4582864.
10. Albarino CG, Palacios G, Khristova ML, Erickson BR, Carroll SA, Comer JA, Hui J, Briese T, St George K, Ksiazek TG, Lipkin WI, Nichol ST. 2010. High diversity and ancient common ancestry of lymphocytic choriomeningitis virus. *Emerg Infect Dis* 16(7):1093-1100. doi: 10.3201/eid1607.091902.
11. Ackermann R, Bloedhorn H, Kupper B, Winkens I, Scheide W. 1964. Spread of the lymphocytic choriomeningitis virus among West German mice. I. Investigations mostly on domestic mice (*Mus musculus*). *Zentralbl Bakteriol* 194:407-430.
12. Becker SD, Bennett M, Stewart JP, Hurst JL. 2007. Serological survey of virus infection among wild house mice (*Mus domesticus*) in the UK. *Lab Anim.* 41:2229-2238.
13. Morita C, Matsuura Y, Fujii H, Joh K, Baba K, Kato M, Hisada M. 1991a. Isolation of lymphocytic choriomeningitis virus from wild house mice (*Mus musculus*) in Osaka Port Japan. *J Vet Med Sci* 53:889–892.
14. Morita C, Matsuura Y, Kawashima E, Takahashi S, Kawaguchi J, Iida S, Yamanaka T, Jitsukawa W. 1991b. Seroepidemiological survey of lymphocytic choriomeningitis virus in wild house mouse (*Mus musculus*) in Yokohama Port Japan. *J Vet Med Sci* 53:219–222.
15. Moro D, Lloyd ML, Smith AL, Shellam GR, Lawson MA. 1999. Murine viruses in an island population of introduced house mice and endemic short-tailed mice in Western Australia. *J Wildlife Dis* 35:301–310.
16. Childs JE, Glass GE, Korch GW, Ksiazek TG, Leduc JW. 1992. Lymphocytic choriomeningitis virus infection and house mouse (*Mus musculus*) distribution in urban Baltimore. *Am J Trop Med Hyg.* 47:27–34.

17. Morita C, Tsuchiya K, Ueno H, Muramatsu Y, Kojimahara A, Suzuki H, Miyashita N, Moriwaki K, Jin ML, Wu XL, Wang FS. 1996. Seroepidemiological survey of lymphocytic choriomeningitis virus in wild house mice in China with particular reference to their subspecies. *Microbiol Immunol* 40:313-315.
18. Lledó L, Gegúndez MI, Saz JV, Bahamontes N, Beltrán M. 2003. Lymphocytic choriomeningitis virus infection in a province of Spain: analysis of sera from the general population and wild rodents. *J Med Virol* 70(2):273-275.
19. Pritchett-Corning KR, Cosentino J, Clifford, CB. 2009. Contemporary prevalence of infectious agents in laboratory mice and rats. *Lab Anim* 43:165-173. doi: 10.1258/la.2008.008009.
20. Mähler M, Köhl WA. 2009. Serological survey to evaluate contemporary prevalence of viral agents and *Mycoplasma pulmonis* in laboratory mice and rats in western Europe. *Lab Anim* 38(5):161-165.
21. Schoondermark van de Ven EME, Philipse-Bergmann IMA, van der Logt JTM. 2006. Prevalence of naturally occurring viral infections, *Mycoplasma pulmonis* and *Clostridium piliforme* in laboratory rodents in western Europe screened from 2000 to 2003. *Lab Anim* 40:137-143.
22. Zenner L, Regnault JP. 2000. Ten-year long monitoring of laboratory mouse and rat colonies in French facilities: a retrospective study. *Lab Anim* 34:76-83.
23. Liang CH, Shih A, Chang YH, Liu CW, Lee YT, Hsieh WC, Huang YL, Huang WT, Kuang CH, Lee KH, Zhuo YX, Ho SY, Liao SL, Chiu YY, Hsu CN, Liang SC, Yu CK. 2009. Microbiological contamination of laboratory mice and rats in Taiwan from 2004-2007. *J Am Assoc Lab Anim Sci* 48(4):381-386.
24. Sato H, Miyata H. 1986. Detection of lymphocytic choriomeningitis virus antibody in colonies of laboratory animals in Japan. *Jikken Dobutsu* 35:189-192.
25. Genovesi EV, Peters CJ. 1987a. Immunosuppression-induced susceptibility of inbred hamsters (*Mesocricetus auratus*) to lethal disease by lymphocytic choriomeningitis virus infection. *Arch Virol* 97:71-76.
26. Genovesi EV, Peters CJ. 1987b. Susceptibility of inbred Syrian golden hamsters (*Mesocricetus auratus*) to lethal disease by lymphocytic choriomeningitis virus. *P Soc Exp Biol Med* 185:250-261.
27. Nicklas W, Kraft V, Meyer B. 1993. Contamination of transplantable tumors, cell lines, and monoclonal antibodies with rodent viruses. *Lab Anim Sci* 43(4):296-300.
28. Van der Zeijst BA, Noyes BE, Mirault ME, Parker B, Osterhaus ADME, Swyryd EA, Bleumink N, Horzinek MC, Stark GR. 1983. Persistent infection of some standard cell lines by lymphocytic choriomeningitis virus: Transmission of infection by intracellular agent. *J Virol* 48(1):249-261.
29. Riera L, Castillo E, Del Carmen Saavedra M, Priotto J, Sottosanti J, Polop J, Ambrosio AM. 2005. Serological study of LCMV in an inner city of Argentina. *J Med Virol* 76:285-289.
30. Stephensen CB, Blount SR, Lanford RE, Holmes KV, Montali RJ, Fleenor ME, Shaw JF. 1992. Prevalence of serum antibodies against lymphocytic choriomeningitis virus in selected populations from two U.S. cities. *J Med Virol* 38:27-31.
31. Ackermann R. 1973. Epidemiologic aspects of lymphocytic choriomeningitis in man. In F. Lehmann-Grube (ed.): *Lymphocytic choriomeningitis virus and other arenaviruses*. Springer-Verlag New York. p. 233-237
32. Forster U, Wachendorfer G. 1973. Inapparent infection of Syrian hamsters with the virus of lymphocytic choriomeningitis. In F. Lehmann-Grube (ed.): *Lymphocytic choriomeningitis virus and other arenaviruses*. Springer-Verlag New York. p. 113-120.

33. Parker JC, Igel HJ, Reynolds RK, Lewis AM Jr, Rowe WP. 1976. Lymphocytic choriomeningitis virus infection in fetal, newborn and young adult Syrian hamsters (*Mesocricetus auratus*). *Infect Immun* 13(3):967-981.
34. Lehmann-Grube F. 1971. Lymphocytic choriomeningitis virus. *Virology monographs* Vol. 10. Springer-Verlag New York.
35. Montali RJ, Connolly BM, Armstrong DL, Scanga CA, Holmes KV. 1995. Pathology and immunohistochemistry of callitrichid hepatitis, an emerging disease of captive new world primates caused by lymphocytic choriomeningitis virus. *Am J Pathol* 148(5):1441-1449.
36. Ackermann R, Kalter SS, Hebling RL, McSullough B, Eichberg J, Rodriguez AR. 1979. Fetal infection of the Baboon (*Papio cynocephalus*) with lymphocytic choriomeningitis virus. *Arch Virol* 60:311-323.
37. Wilsnack RE. 1966. Lymphocytic choriomeningitis. *Natl Cancer Inst Monogr* 20:77-92.
38. Baker DG. 1998. The natural pathogens of lab mice, rats, rabbits and their effect on research. *Clin Microbiol Rev* 11(2):242.
39. Buchmeier MJ, Welsh RM, Dutko FJ, Oldstone MB. 1980. The virology and immunobiology of lymphocytic choriomeningitis virus infection. *Adv Immunol* 30:275-331.
40. Bishop DIL, Auperin DD. 1987. Arenavirus gene structure and organization. *Curr Top Microbiol Immunol* 133:5-17.
41. Barthold SW, Smith AL. 2007. Lymphocytic choriomeningitis virus. In: Fox JG, Barthold SW, Davisson MT, Newcomer CE, Quimby FW, Smith AL (Eds). *The mouse in biomedical research*, 2nd Ed, Vol 2. Waltham (MA): Academic Press, pp179-213.
42. Takagi T, Ohsawa M, Morita C, Sato H, Ohsawa K. 2012. Genomic analysis and pathogenic characteristics of Lymphocytic Choriomeningitis Virus strains isolated in Japan. *Comp Medicine* 62(3):185-192.
43. Yama IN, Cazaux B, Britton-Davidian J, Moureau G, Thirion L, de Lamballerie X, Dobigny G, Charrel RN. 2012. Isolation and characterization of a new strain of lymphocytic choriomeningitis virus from rodents in southwestern France. *Vector Borne Zoonotic Dis* 12(10):893-903.
44. Plume JM, Todd D, Bonthius DJ. 2019. Viral strains determines disease symptoms, pathology, and immune response in neonatal rats with lymphocytic choriomeningitis virus infection. *Viruses* 11(6) pii:552. doi: 10.3390/v11060552.
45. Traub E. 1936a. Persistence of lymphocytic choriomeningitis virus in immune animals and its relation to immunity. *J. Exp Med* 63:847-861.
46. Traub E, 1936b. An epidemic in a mouse colony due to the virus of acute lymphocytic choriomeningitis. *J Exp Med* 63:533-548.
47. Skinner HH, Knight EH. 1973. Natural routes for postnatal transmission of murine lymphocytic choriomeningitis. *Lab Anim* 7:171-184.
48. Skinner HH, Knight EH, Buckley LS. 1976. The hamster as a secondary reservoir host of lymphocytic choriomeningitis virus. *J Hyg Camb* 76:299- 306.
49. Zinkernagel RM, Leist T, Hengartner H, Althage A. 1985. Susceptibility to lymphocytic choriomeningitis virus isolates correlates directly with early and high cytotoxic T cell activity, as well as with footpad swelling reaction and all 3 are regulated by H2D. *J Exp Med* 162:2125-45.

50. Knust B, Ströher U, Edison L, Albariño CG, Lovejoy J, Armeanu E, House J, Cory D, Horton C, Fowler KL, Austin J, Poe J, Humbaugh KE, Guerrero L, Campbel SI, Gibbons A, Reed Z, Cannon D, Manning C, Petersen B, Metcalf D, Marsh B, Nichol ST, Rollin PE. 2014. Lymphocytic choriomeningitis virus in employees and mice at multipremises feeder-rodent operation United States 2012. *Emerg Infect Dis* 20(2):240-47. www.cdc.gov/eid Vol. 20 No.2.
51. Peralta LA, Languens M, Ponzinibbio C, Laguens RP 1990: Infection of guinea pigs with two strains of lymphocytic choriomeningitis virus. *Medicina (B Aires)* 50(3):225-229.
52. Bonthius DJ, Mahoney J, Buchmeier MJ, Karacay B, Taggard D. 2002. Critical role for glial cells in the propagation and spread of lymphocytic choriomeningitis virus in the developing rat brain. *J Virol* 76(13):6618-35. doi:10.1128/JVI.76.13.6618-6635.2002.
53. Oldstone BA, Dixon FJ. 1969. Pathogenesis of chronic disease associated with persistent lymphocytic choriomeningitis viral infection I. Relationship of antibody production to disease in neonatally infected mice. *J Exp Med* 129(3):483-505.
54. Hirsch E. 1976. Sensorineural deafness and labyrinth damage due to lymphocytic choriomeningitis. Report of a case. *Archiv Otolaryngol* 102:499-500.
55. Oldstone BA, Dixon FJ. 1970. Pathogenesis of chronic disease associated with persistent lymphocytic choriomeningitis viral infection. II Relationship of the anti-lymphocytic choriomeningitis immune response to tissue injury in chronic lymphocytic choriomeningitis disease. *J Exp Med* 131(1):1-19.
56. Coutelier JP, Johnson SJ, El-Idrissi M, Pfau CJ. 1994. Involvement of CD4+ cells in lymphocytic choriomeningitis virus-induced autoimmune anemia and hypergammaglobulinemia. *J Autoimmun* 5:589-599.
57. Smelt SC, Borrow P, Kunz S, Cao W, Tishon A, Lewicki H, Campbell KP, Oldstone MB. 2001. Differences in affinity of binding of lymphocytic choriomeningitis virus strains to the cellular receptor alpha-dystroglycan correlate with viral tropism and disease kinetics. *J Virol* 75:448-457.
58. Lukashevich IS, Rodas JD, Tikhonov II, Zapata JC, Yang Y, Djavani M, Salvato MS. 2004. LCMV-mediated hepatitis in rhesus macaques: WE but not ARM strain activates hepatocytes and induces liver regeneration. *Arch Virol* 149,2319-2336.
59. Gossmann J, Lohler J, Utermohlen O, Lehmann-Grube F. 1995. Murine hepatitis caused by lymphocytic choriomeningitis virus. II Cells involved in pathogenesis. *Lab Invest* 72:559-570.
60. Lohler J, Gossmann J, Kratzberg T, Lehmann-Grube F. 1994. Murine hepatitis caused by lymphocytic choriomeningitis virus. *Lab Invest.* 70:263-278.
61. Mook DM, Painter JA, Pullium JK, Ford TR, Dillehay DL, Pearce BD. 2004. Urolithiasis associated with experimental lymphocytic choriomeningitis virus inoculation in Lewis rats. *Comp Med* 54(3):318-323.
62. Genovesi EV, Johnson AJ, Peters CJ. 1989. Delayed type hypersensitive response of inbred strains of Syrian golden hamsters (*Mesocricetus auratus*) to lethal or nonlethal lymphocytic choriomeningitis virus (LCMV) infections. *Microb Pathog* 8:347-360.
63. Riviere Y, Ahmed R, Southern PJ, Buchmeier MJ, Oldstone MB. 1985. Genetic mapping of lymphocytic choriomeningitis virus pathogenicity: virulence in guinea pigs is associated with the L RNA segment. *J Virol* 55:704-709.
64. Ronco P, Rivière Y, Thoua Y, Bandu MT, Guillon JC, Verroust P, More-Maroger L. 1981. Lymphocytic choriomeningitis infection in the nude mouse. An immunological study. *Immunology* 43(4):763-770.
65. Christoffersen PJ, Volkert M, Rygaard J. 1976. Immunological unresponsiveness of nude mice to LCM virus infection. *Acta Pathol Microbiolo Scand* 84C(6):520-523.

66. Anderlik P, Bános Z, Szeri I, Barna Z. 1992. Effect of pretreatment with immunological agents on the outcome of lymphocytic choriomeningitis virus infection in athymic (nude) and euthymic mice. *Acta Pharm Hung* 62(4):167-171.
67. Meyer HM Jr, Johnson RT, Crawford IP, Dascomb HE, Rogers NG. 1960. Central nervous system syndrome of viral etiology. *Am J Med* 29:334-47. doi:10.1016/0002-9343(60)90029-2.
68. Smith AL, Singleton GR, Hansen GM, Shellam G. 1993. A serologic survey for viruses and *Mycoplasma pulmonis* among wild house mice (*Mus domesticus*) in southeastern Australia. *J Wildlife Dis* 29:219-229.
69. Rousseau MC, Saron MF, Brouqui P, Bourgeade A. 1977. Lymphocytic choriomeningitis virus in southern France: four case reports and review of the literature. *Eur J Epidemiol* 13:817-823.
70. Marrie TJ, Saron ME. 1998. Seroprevalence of lymphocytic choriomeningitis virus in Nova Scotia. *Am J Trop Med Hyg* 58:47-49.
71. Knust B, Holman RC, Redd J, Mehal JM, Grube SM, MacNeil A, Cheek J, Rollin PE. 2013. Lymphocytic choriomeningitis virus infections among American Indians. *Emerg Infect Dis* 19(2):328-329.
72. Knust B, MacNeil A, Wong SJ, Backenson PB, Gibbons A, Rollin PE, Nichol ST. 2011. Exposure to lymphocytic choriomeningitis virus, New York USA. *Emerg Infect Dis* 17(7):1324-25. doi:10.3201/eid1707.101349.
73. Folk S, Steinbecker S, Windmeyer J, Macneil A, Campbell S, Rollin PE. 2011. Lymphocytic choriomeningitis with severe manifestations, Missouri, USA. *Emerg Infect Dis* 17(10):1973-74. doi:10.3201/eid1710.110911.
74. Komrower GM, Williams BL, Stones PB. 1955. Lymphocytic choriomeningitis in the newborn, probable transplacental infection. *Lancet* 2;268(6866):697-698; doi: 10.1016/s0000140-6736(55)91066-1067.
75. Larsen PD, Chartrand SA, Tomashek KM, Hause LG, Ksiazek TG. 1993. Hydrocephalus complicating lymphocytic choriomeningitis virus infection. *Pediatr Infect Dis J* 12(6):528-531.
76. Childs JE, Klein SL, Glass GE. 2019. A case study of two rodent-borne viruses: Not always the same old suspects. *Front Ecol Evol* 7(35):1-9; doi:10.3389/fevo.2019.00035.
77. MacNeil A, Ströher U, Farnon E, Campbell S, Cannon D, Paddock CD, Drew CP, Kuehnert M, Knust B, Gruenenfelder R, Zaki SR, Rollin PE, Nichol ST and the LCMV Transplant Investigation Team. 2012. Solid organ transplant-associated lymphocytic choriomeningitis, United States 2011. *Emerg Infect Dis* 18(8):1256-1262. www.cdc.gov/eid.
78. Amman BR, Pavlin BJ, Albarino CG, Comer JA, Erickson BR, Oliver JB, Sealy TK, Vincent MJ, Nichol ST, Paddock CD, Tumpey AJ, Wagoner KD, Glauer RD, Smith KA, Wimpisinger KA, Parsely MS, Wyrick P, Hannafin CH, Bandy U, Zaki S, Rollin PE, Ksiazek TG. 2007. Pet rodents and fatal lymphocytic choriomeningitis in transplant patients. *Emerg Infect Dis* 13(5):719-725.
79. Dräger S, Marx AF, Pigny F, Cherlipillod P, Eisermann P, Sendi P, Widmer AF. 2019. Lymphocytic choriomeningitis virus meningitis after needlestick injury: a case report. *Antimicrob Resist Infect Control* 8:77-81.
80. Dykewicz CA, Dato VM, Fisher-Hoch SP, Howarth MV, Perez-Oronoz GI, Ostroff SM, Gary H Jr, Schonberger LB, McCormick JB. 1992. Lymphocytic choriomeningitis outbreak associated with nude mice in a research institute. *JAMA* 11;267(10):1349-1353.
81. Barton LL, Budd SC, Morfitt WS, Peters CJ, Ksiazek TG, Schindler RF, Yoshino MT. 1993. Congenital lymphocytic choriomeningitis virus infection in twins. *Pediatr Infect Dis J* 12(11):942-946.

82. Bonthius DL, Wright R, Tseng B, Marco E, Karacay B, Larsen PD. 2007. Congenital lymphocytic choriomeningitis virus infection: spectrum of disease. *Ann Neurol* 62:347-355.
83. Enders G, Varho-Göbel M, Löhler J, Terletkaia-Ladwig E, Eggers M. 1999. Congenital lymphocytic choriomeningitis virus infection: an underdiagnosed disease. *Pediatric Infect Dis J* 18:652-655.
84. Kohler M, Rüttner B, Cooper S, Hengartner H, Zinkernagel RM. 1990. Enhanced tumor susceptibility of immunocompetent mice infected with lymphocytic choriomeningitis virus. *Cancer Immunol Immunother* 32(2):117-124.
85. Nadel EM, Haas VH. 1956. Effect of the virus of lymphocytic choriomeningitis virus on the course of leukemia in guinea pigs and mice. *J Nat Cancer Inst* 17:221-231.
86. Skinner HH, Knight EH, Lancaster MC. 1980. Lymphomas associated with a tolerant lymphocytic choriomeningitis virus infection in mice. *Lab Anim* 14:117-121.
87. Youn JK, Barski G. 1966. Interference between Lymphocytic Choriomeningitis Virus and Rauscher Leukemia in Mice. *J Nat. Cancer Inst* 37:381-388.
88. Oxenius A, Bachmann MF, Zinkernagel RM, Hengartner H. 1998. Virus-specific MHC-class II-restricted TCR-transgenic mice: effects on humoral and cellular immune response after viral infection. *Eur J Immun* 28:390-400
89. Thomson AR, Bro-Jorgensen K, Jensen BL. 1982. Lymphocytic choriomeningitis virus-induced immunosuppression: evidence for viral interference with T-cell maturation. *Infect Immun* 37:981-986.
90. Saron MF, Shidani B, Nohori JC, Guillon JC, Truffa-Bachi P. 1990. Lymphocytic choriomeningitis virus-induced immunodepression: inherent defect of B and T lymphocytes. *J Virol* 64:4076-4083.
91. Saron MF, Colle JH, Dautry-Vaarsat A, Truffa-Bachi P. 1991. Activated T lymphocytes from mice infected by lymphocytic choriomeningitis virus display high affinity IL-2 receptors but not proliferate in response to IL-2. *J Immunol* 147:4333-4337.
92. Colle JH, Saron MF, Truffa-Bachi P. 1993. Altered cytokine genes expression by con A-activated spleen cells from mice infected by lymphocytic choriomeningitis virus. *Immunol Lett.* 35:247-253.
93. El-Azami-El-Idrissi M, Mazza G, Monteyne P. 1998. Lymphocytic choriomeningitis virus- induced alterations of T-helper-mediated response in mice developing autoimmune hemolytic anemia during the course of infection. *P Soc Exp Biol Med* 218:349-356.
94. Yang HY, Dundon UL, Nahill SR, Welsh RM. 1989. Virus-induced polyclonal cytotoxic T lymphocyte stimulation. *J Immunol* 142:1710-1718.
95. Bocharov GA. 1998. Modelling the dynamics of LCMV infection in mice: conventional and exhaustive CTL responses. *J Theor Biol* 192:283-308.
96. Jamieson BD, Butler LD, Ahmed R. 1987. Effective clearance of a persistent viral infection requires cooperation between virus-specific Lyt2+ T cells and nonspecific bone marrow derived cells. *J Virol* 61:3930-3937.
97. Truong P, Heydari S, Garidou L, McGavern DB. 2009: Persistent viral infection elevates central nervous system MHC class I through chronic production of interferons. *J Immun* 183:3895-3905.
98. Ahmed R, Jamieson BD, Porter D. 1987. Immune therapy of a persistent and disseminated viral infection. *J Virol* 61(12):3920-3929.
99. Orange JS, Wolf SF, Biron CA. 1994. Effects of IL-12 on the response and susceptibility to experimental viral infections. *J Immunol* 152:1253-1264.
100. Orange JS, Salazar-Mather T, Opal SM, Spenser RL, Miller AH, McEwen BS, Biron CA. 1995. Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids. *Journal Exp Med* 181:901-914.

101. Sandberg K, Eloranta ML, Campbell IL. 1994. Expression of alpha/beta interferons (IFN-alpha/beta) and their relationship to IFN-alpha/beta induced genes in lymphocytic choriomeningitis. *J Virol* 68:7358-7366.
102. Binder D, Fehr J, Hengartner H, Zinkernagel RM. 1997. Virus-induced transient bone marrow aplasia. *J Exp Med*. 185:517-530.
103. Oldstone MB, Ahmed R, Buchmeier MJ, Blount P, Toshon A. 1985. Perturbation of differentiated functions during viral infection in vivo. I. Relationship of lymphocytic choriomeningitis virus and host strains to growth hormone deficiency. *Virology* 142:158-174.
104. Valsamakis A, Riviere Y, Oldstone MBA 1987. Perturbation of differentiated functions in vivo during persistent viral infection III. Decreased growth hormone mRNA. *Virology* 156(2),214-220.
105. Abdel-Hakeem MS. 2019. Viruses teaching immunology: Role of LCMV model and human viral infections in immunological discoveries. *Viruses* 11(106):1-19. doi: 10.3390/v11020106.
106. Zhou X, Ramachandran S, Mann M, Popkin DL. 2012. Role of lymphocytic choriomeningitis virus (LCMV) in understanding viral immunology: past, present and future. *Viruses* 4:2650-2669. doi: 10.33390/v4112650.
107. Oldstone MB; Dixon FJ. 1967. Lymphocytic choriomeningitis: Production of antibody by "tolerant" infected mice. *Science* 158:1193–1195.
108. Zinkernagel RM, Doherty PC. 1974. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. *Nature* 248:701-702.
109. Zinkernagel RM, Doherty PC. 1974. Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis. *Nature* 251:547–548.
110. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. 1993. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. *Nature* 362:758–761.
111. Gilden DH, Cole GA, Nathanson N. 1972. Immunopathogenesis of acute central nervous system disease produced by lymphocytic choriomeningitis virus. II. Adoptive immunization of virus carriers. *J Exp Med* 135:874–889.
112. Fousteri G, Jhakatia AD. 2019. Viral infections and autoimmune disease: roles of LCMV in delineating mechanisms of immune tolerance. *Viruses*, 11:885-896.

Disclaimer

Any use of GV-SOLAS booklets (publications) and statements and the application of the information contained therein are at the express risk of the user. Neither GV-SOLAS nor the authors can accept liability for any accidents or damages of any kind arising from the use of a publication (e.g. resulting from the absence of safety instructions), irrespective of legal grounds. Liability claims against GV-SOLAS and the author for damages of a material or non-material nature caused by the use or non-use of the information or by the use of erroneous and/or incomplete information are in principle excluded. Legal claims and claims for damages are thus excluded. The work, including all content, has been compiled with utmost care. However, GV-SOLAS and the authors assume no responsibility for the currentness, correctness, completeness or quality of the information provided. Printing errors and incorrect information cannot be completely ruled out. GV-SOLAS and the authors accept no liability for the currentness, correctness and completeness of the content of the publications or for printing errors. GV-SOLAS and the authors accept no legal responsibility or liability in any form for incorrect statements and consequences arising therefrom. Responsibility for the content of the internet pages printed in these publications lies solely with the owner of the websites concerned. GV-SOLAS and the authors have no influence on the design and content of third-party websites. GV-SOLAS and the authors therefore distance themselves from all third-party content. Responsibility within the meaning of press legislation lies with the board of GV-SOLAS.